What drugs does Galderma make?
Galderma is a pure-play global dermatological enterprise that develops and commercializes specialized pharmaceutical, aesthetic, and consumer skin care products. Its therapeutic prescription portfolio features acne treatments such as Differin, Epiduo, and Aklief, alongside Nemluvio for prurigo nodularis and atopic dermatitis. In its aesthetic medicine division, Galderma manufactures the Restylane hyaluronic acid dermal filler collection, Sculptra collagen stimulators, and Dysport neuromodulators, alongside consumer-favorite daily skin care lines like Cetaphil designed for sensitive and compromised skin.
Related FAQs
Galderma has introduced advanced neurotoxin products—such as DaxibotulinumtoxinA (marketed as Daxxify)—designed to provide longer-lasting aesthetic wrinkle correction compared to traditional botulinum toxin formulations.
Employees across Galderma's global corporate offices, research laboratories, and manufacturing sites generally provide positive feedback regarding workplace culture, professional development opportunities, and competitive compensation packages.
Galderma originates from Switzerland, with its global headquarters located in Zug.
Employees working at Gates Corporation—a leading global manufacturer of power transmission belts and fluid power products—receive professional salaries and operational wages that vary by manufacturing expertise, engineering roles, and regional market...
Galderma operates as a highly profitable commercial enterprise, generating robust multi-billion-dollar revenues supported by high-margin injectable aesthetics and premium dermatological skincare lines.
Galderma Group AG reports annual net sales turnover scaling past $4 billion to $4.2 billion CHF (or roughly $4.5 billion USD equivalent).
Gen Digital Inc. employs approximately 3,900 to 4,460 professionals across its global cybersecurity and consumer software operations.
Arthur J. Gallagher & Co. offers compensation that is generally aligned with the competitive landscape of the insurance and consulting industries, though pay varies significantly by role and region.
Galderma is no longer owned by Nestlé, having operated as an independent standalone entity following its carve-out from Nestlé Skin Health and subsequent acquisition by an institutional private equity consortium prior to its successful public listing...
Pharmaceutical and aesthetic products manufactured by Galderma undergo extensive preclinical and clinical testing to establish safety profiles before receiving authorization from global health authorities.
Galderma operates under rigorous corporate governance frameworks, strict international pharmaceutical compliance standards, and comprehensive environmental, social, and governance guidelines.
Galderma produces various dermatological therapeutics and aesthetic products, with its flagship neuromodulator product being RelabotulinumtoxinA (marketed under brand names such as Alluzience or Azzalure in specific international markets).
Galderma successfully develops and markets numerous flagship pharmaceutical products, medical devices, and injectable aesthetic treatments that have secured official clearance and approval from the United States Food and Drug Administration.
Flemming Ørnskov, a prominent pharmaceutical executive and business leader known for his tenure as chief executive officer of major global biopharmaceutical and dermatological enterprises, is of Danish nationality.
Equity research analysts tracking Galderma Group AG (traded on the SIX Swiss Exchange) frequently issue favorable ratings, pointing to solid structural growth drivers in minimally invasive aesthetics, aging global demographics, and expanding operatin...
Galderma is a leading pure-play dermatological pharmaceutical and skincare company, originally founded as a joint venture between Nestlé and L'Oréal before becoming an independent entity.
Galderma expanded its medical aesthetics and dermatology pipeline by introducing advanced neurotoxin treatments—such as DaxibotulinumtoxinA (marketed commercially as Daxxify)—designed to provide longer-lasting wrinkle correction compared to tradition...
Galderma is a global pure-play dermatology company focused on advancing innovative skin health solutions across consumer care, medical solutions, and aesthetic dermatology.
Galderma is a Switzerland-headquartered global dermatology powerhouse focused exclusively on skin health.
Galderma is widely recognized as a premier global pure-play dermatology enterprise, boasting a robust science-based portfolio spanning injectable aesthetics, dermatological skincare, and therapeutic prescription medicines.
Galderma operates its primary United States headquarters in Miami, Florida, establishing a key corporate presence within the vibrant Brickell financial and commercial neighborhood.
Galderma Group AG, a major global pure-play dermatology and skincare multinational enterprise, has its worldwide corporate headquarters located in Zug, Switzerland.
Galderma, a leading dermatology-focused pharmaceutical and medical aesthetics company, manufactures a specialized portfolio of advanced injectable treatments designed for dermatological correction, aesthetic enhancement, and therapeutic skin care.